Bastien Gerby
Overview
Explore the profile of Bastien Gerby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Largeaud L, Fregona V, Jamrog L, Hamelle C, Dufrechou S, Prade N, et al.
Blood Cancer J
. 2025 Jan;
15(1):7.
PMID: 39885120
GATA2 germline mutations lead to a syndrome characterized by immunodeficiency, vascular disorders and myeloid malignancies. To elucidate how these mutations affect hematopoietic homeostasis, we created a knock-in mouse model expressing...
2.
Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog L, et al.
J Exp Med
. 2023 Nov;
221(1).
PMID: 37930337
B cell acute lymphoblastic leukemia (B-ALL) is a multistep disease characterized by the hierarchical acquisition of genetic alterations. However, the question of how a primary oncogene reprograms stem cell-like properties...
3.
Veiga D, Tremblay M, Gerby B, Herblot S, Haman A, Gendron P, et al.
Front Immunol
. 2022 Apr;
13:867443.
PMID: 35401501
Early T-cell development is precisely controlled by E proteins, that indistinguishably include HEB/TCF12 and E2A/TCF3 transcription factors, together with NOTCH1 and pre-T cell receptor (TCR) signalling. Importantly, perturbations of early...
4.
Fregona V, Bayet M, Gerby B
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771671
Our understanding of the hierarchical structure of acute leukemia has yet to be fully translated into therapeutic approaches. Indeed, chemotherapy still has to take into account the possibility that leukemia-initiating...
5.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, et al.
Blood Adv
. 2021 Oct;
6(2):386-398.
PMID: 34638130
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and in a substantial proportion of cases to acute...
6.
Duployez N, Jamrog L, Fregona V, Hamelle C, Fenwarth L, Lejeune S, et al.
Blood
. 2020 Oct;
137(10):1424-1428.
PMID: 33036026
No abstract available.
7.
8.
Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, et al.
Proc Natl Acad Sci U S A
. 2018 Sep;
115(41):10357-10362.
PMID: 30257940
is a well-known haploinsufficient tumor suppressor gene in human B-cell precursor acute lymphoblastic leukemia (B-ALL) and is involved in various chromosomal translocations that fuse a part of PAX5 with other...
9.
Cresson C, Peron S, Jamrog L, Rouquie N, Prade N, Dubois M, et al.
Oncotarget
. 2018 Sep;
9(67):32841-32854.
PMID: 30214688
Pax5 is the guardian of the B cell identity since it primes or enhances the expression of B cell specific genes and concomitantly represses the expression of B cell inappropriate...
10.
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells
Gerby B, Veiga D, Krosl J, Nourreddine S, Ouellette J, Haman A, et al.
J Clin Invest
. 2016 Nov;
126(12):4569-4584.
PMID: 27797342
Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein,...